Tuberculosis

  • USAID Global Accelerator to End Tuberculosis: Partnership Statements

    Learn More
  • U.S. Government Achieves 2018 TB Research and Development Funding Target

    Learn More
  • USAID announces the TB Local Organizations Network Annual Program Statement as a key component of the Global Accelerator to End Tuberculosis.

    Learn More
  • To accelerate action on TB, USAID has announced an innovative model, “The Global Accelerator to End Tuberculosis.”

    Learn More
  • The U.S. Government Departments and Agencies charged with implementing the National Action Plan for Combating Multidrug-Resistant Tuberculosis continue to make notable progress towards achieving the Plan's established milestones.

    Learn More
  • Administrator Green spoke about ending the tuberculosis epidemic in India during his November 2017 trip.

    Learn More
  • As the lead U.S. Government agency for global TB care, USAID works with partners to reach every person with TB, cure those in need of treatment and prevent new TB infections.

    Learn More

At USAID, we focus our investments on strengthening national TB strategies and programs through bilateral programs in priority countries with high rates of TB, drug-resistant TB and HIV-associated TB.

10 million
new cases of TB (estimated, range, 9.0–11.1 million)
1.2 million
TB deaths (range, 1.1–1.3 million)
500,000
new drug-resistant TB cases (estimated)
156,000
drug-resistant TB cases on treatment

The U.S. Agency for International Development (USAID) supports high-quality screening, diagnosis and treatment services for millions of people affected by TB and multidrug-resistant tuberculosis (MDR-TB). In Fiscal Year 2018, with investments of $265 million focused primarily in 23 countries with bilateral TB funds, the U.S. Government achieved the following results in collaboration with each country's National TB Program:

 

23

Countries with bilateral programs

55

Countries received technical assistance

4,600,000

TB cases detected

14%

Increase in case notifications

89%

Treatment Success Rate

98,435

Individuals with DR-TB started on appropriate treatment

37,000,000

GeneXpert cartridges procured under concessional pricing (cumulative)

78

Countries that used the Bedaquiline Donation Program (cumulative)

40,000

Health workers trained

23

Countries completed drug-resistance surveys (cumulative)

22

Completed TB prevalence surveys (cumulative)

7

Research studies supported that focused on new treatment regimen

USAID's investments contributed to an estimated 58 million lives saved from 2000-2018, including people co-infected with HIV/AIDS.

 

What We Do

USAID works with partner governments to:

  • Prevent TB transmission and renew efforts to find the missing TB cases
  • Strengthen the capacity of national TB programs
  • Build country capacity to use existing resources and to turn evidence into policy
  • Expand the development of new TB diagnostics, drugs and vaccines

Last updated: November 26, 2019

Share This Page